Avalyn Pharma's Upcoming Investor Conferences
Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies for severe pulmonary diseases, is gearing up for participation in multiple investor conferences this December. The leadership team is excited to engage with investors and share their vision for transforming treatment options for patients suffering from life-threatening respiratory conditions.
Key Conference Details
The two main conferences Avalyn will be attending this December are set to highlight important discussions surrounding healthcare advancements and innovations in the biopharmaceutical sector. Attendees can expect insightful presentations and discussions led by top executives from Avalyn.
7th Annual Evercore HealthCONx Conference
This prestigious conference will feature Avalyn's management team on December 3, at 3:50 p.m. ET. The format includes a fireside chat along with one-on-one meetings, providing a unique opportunity for investors to interact directly with the company's leaders.
Participants for Evercore Conference
The Evercore HealthCONx Conference will include Lyn Baranowski, CEO; Douglas Carlson, CFO, CBO; and Howard M. Lazarus, CMO of Avalyn. Their participation underlines the company's commitment to engaging with stakeholders and investors in the healthcare community.
Citi's 2024 Global Healthcare Conference
Following Evercore, Avalyn will continue their engagement at Citi's 2024 Global Healthcare Conference on December 4 at 11:00 a.m. ET. Similar to the previous conference, the format will consist of a fireside chat and exclusive one-on-one meetings to discuss the company's developments.
Participants for Citi's Conference
Once again, Lyn Baranowski, Douglas Carlson, and Howard M. Lazarus will represent Avalyn, providing insights into their innovative approaches in treating rare respiratory diseases.
About Avalyn Pharma
Avalyn Pharma is on the cutting edge of biopharmaceutical innovation, concentrating on inhaled therapies designed for rare respiratory diseases, such as pulmonary fibrosis and interstitial lung diseases (ILD). Pulmonary fibrosis not only deteriorates lung function but also significantly impacts patients' quality of life. Current treatment alternatives have limitations, including serious side effects that may deter their use.
Avalyn is working diligently to develop advanced inhaled formulations that aim to directly target the lungs while minimizing systemic exposure. Their foremost program, designated as AP01, constitutes an optimized inhaled formulation of pirfenidone and is currently being explored in the MIST Phase 2b Study for progressive pulmonary fibrosis. So far, AP01 has been tested in over 150 individuals, showcasing impressive clinical proof-of-concept and yielding better safety and efficacy results compared to existing treatments.
Future Developments
In addition to AP01, Avalyn is progressing toward initiating a Phase 1b study for its second program, labeled AP02, which features inhaled nintedanib aimed at addressing idiopathic pulmonary fibrosis (IPF). Such innovative initiatives mark Avalyn as a forward-thinking participant in the biopharmaceutical landscape.
Contact Information
Investor Contact:
Alex Straus
THRUST Strategic Communications
alex@thrustsc.com
ir@avalynpharma.com
Media Contact:
Marites Coulter
Deerfield Group
marites.coulter@deerfieldgroup.com
media@avalynpharma.com
Frequently Asked Questions
What is Avalyn Pharma known for?
Avalyn Pharma specializes in developing inhaled therapies for treating severe pulmonary diseases like pulmonary fibrosis.
What conferences will Avalyn Pharma participate in?
Avalyn Pharma will participate in the Evercore HealthCONx Conference and Citi's 2024 Global Healthcare Conference in December.
Who are the key participants from Avalyn Pharma at the conferences?
The key participants include Lyn Baranowski (CEO), Douglas Carlson (CFO, CBO), and Howard M. Lazarus (CMO).
What is AP01?
AP01 is Avalyn's lead program, an optimized inhaled formulation of pirfenidone, currently undergoing trials for progressive pulmonary fibrosis.
How can I contact Avalyn Pharma?
You can contact Avalyn Pharma through their investor relations email at ir@avalynpharma.com or their media contact at media@avalynpharma.com.
